Erik Kimble, MD

Cellular Immunotherapy, CAR T cells, @fredhutch, @UWMedicine

[Erik Kimble, MD @ekimblepl]

@amjimenezmd @ASTCT @fredhutch Gracias, Antonio!

[Erik Kimble, MD @ekimblepl]

@ASTCT @fredhutch Thank you @ASTCT! I just want to give a shout out to all the fantastic mentors I have been privileged to learn from over the years, especially Cameron Turtle, @bradleybio, @HPKiem, Johnnie Orozco, David Maloney @drkomanduri, and Jan Abkowitz. Hopefully I can pay it forward!

[ASTCT @ASTCT]

Congratulations to ASTCT New Investigator Award recipient Erik Kimble, MD, of @fredhutch. #Tandem25

[Erik Kimble, MD @ekimblepl]

@DrShadeO @ASTCT @fredhutch Thanks so much, Shade! I'm beyond grateful and excited to be a part of this—For context of the picture: I was just reminiscing about the journey, the things in life that inspire me, and how much mentorship and opportunity matter. There is a huge smile there, lol!

[Erik Kimble, MD @ekimblepl]

There are over 1 million individuals of Mexican heritage living in the state of Washington. I am proud and privileged to share this moment as we celebrate 'El Grito' and, officially, the first 'Mexico Week' in Seattle.#Somos #VivaMexico

[Erik Kimble, MD @ekimblepl]

Late breaking abstract! Congrats @mshadman from @fredhutch - senior author on final analysis of the ALPINE study : Zanbrutinib for RR CLL - safer and more tolerable than Ibrutinib with improved PFS.

[Jordan Gauthier @drjgauthier]

Congratulations to @sghmd and all @BMTCTN investigators for setting a new SOC for #GVHD Px after RIC allo-HCT.
Outstanding effort!
⬆️GRFS with PTCy
HR for PTCy-Tac-MMF vs Tac-MTX: 0.64, 95%CI 0.49-0.83, p=0.001
https://t.co/b1iE1mtRgX
#ASH2 #LBA #bmtsm #ASHKudos

[Fred Hutch Cancer Center @fredhutch]

During the Fred Hutch #ASH22 reception, colleagues commemorated the enduring legacy of Dr. Eli Estey, who passed away last year. Estey was a consummate academician whose many contributions to research changed practice in acute myeloid leukemia (AML). https://t.co/kQfGWkgFun

[Erik Kimble, MD @ekimblepl]

@xanhira from our group at @fredhutch presenting data regarding the use of PDL1 blockade in combination with CD19 CAR T cell therapy in a phase 1 trial... fascinating correlative questions. Stop by with questions!!!

[Jordan Gauthier @drjgauthier]

Efficient allogeneic « off-the-shelf » CAR T cell therapies would be a major breakthrough, but so far limited by anti-CAR immune responses.
B2M KO prevents CD8 T-cell reactivity but triggers NK reactivity.
Fascinating #ASH22 session with strategies to prevent the latter 1/x

[Erik Kimble, MD @ekimblepl]

@KFertrin @drbimpesicklemd @Busola_Ol @mlinenb561 @fredhutch at #ASH22!!!

[Erik Kimble, MD @ekimblepl]

Tinkering with the CAR: Great to see science translating to clinic - calibrated CD19 CAR with mutated ITAM motifs - appears to be effective at low doses; toxicity profile appears to be low despite CD28 costim domain. #ASH22

[Jordan Gauthier @drjgauthier]

The 🐢 CAR-T task force still going strong!!! @fredhutch #ASH22

[Erik Kimble, MD @ekimblepl]

Rideshare scene in NOLA reminds me of CAR T cell therapy....
#ASH22 attendees proliferating on arrival...Uber and Lyft prices suuuurgging like IL 6 levels...I am now looking for less toxic vehicles...shuttle perhaps! 😅

[Erik Kimble, MD @ekimblepl]

@drkomanduri @ASH_hematology Hope you had a cafecito on the way!

[Jordan Gauthier @drjgauthier]

Short 🧵highlighting CAR T-cell therapy research from our group @fredhutch @UW soon to be presented at #ASH22 in New Orleans.
@ASH_hematology
#TcellRx #immunonc #leusm #lymsm
1/x

[Fred Hutch Cancer Center @fredhutch]

The Bezos family has committed $710.5 million to Fred Hutchinson Cancer Center to accelerate breakthrough discoveries in cancer and infectious disease research. https://t.co/YN7B5cB74g

[Fred Hutch Cancer Center @fredhutch]

Cancer #clinicaltrials offer the treatments of tomorrow, today. But many cancer patients don't qualify for these trials. Fred Hutch scientists are working with national organizations to help revamp strict eligibility criteria so more patients can enroll. https://t.co/9cxe242sX0

[Erik Kimble, MD @ekimblepl]

Great working on this with you, Ryan!

[Ryan Cassaday @RyanCassaday]

Check out this review on a rapidly-evolving and clinically-relevant topic, #immunotherapy for #ALL in adults. Features great collaboration and new figures by the talented @ekimblepl. #leusm @uwmnewsroom @fredhutch @SeattleCCA

https://t.co/6frq1RP60q

[Erik Kimble, MD @ekimblepl]

@BuckyBrooks Granada has come a long way since I graduated. #classof2004